[Cost-effectiveness of empirical antifungal treatment of haematology patients with a high risk of invasive fungal infection].
Espigado
I
I
D000935:Antifungal Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D036262:Empirical Research; D006402:Hematologic Diseases / Q000188:drug therapy / Q000191:economics / Q000382:microbiology; D006801:Humans; D009181:Mycoses / Q000150:complications / Q000188:drug therapy / Q000191:economics; D012307:Risk Factors; D012720:Severity of Illness Index
D000935:Antifungal Agents